Comorbid disease drives short-term hospitalization outcomes in patients with multiple sclerosis.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
10
07
2018
accepted:
10
03
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
ppublish
Résumé
Readmission is used as a quality indicator and is the primary target outcome for disease-modifying therapy (DMT) for multiple sclerosis (MS). However, data on readmissions for patients with MS are limited. Using the US Nationwide Readmissions Database, we performed a retrospective cohort study of adults hospitalized for MS in 2014. Primary study outcomes were within 30- and 90-day readmissions. Descriptive analyses compared patient, clinical, and hospital variables readmission status. Multivariable logistic regression models estimated the associations between these variables and readmission. Of 16,629 individuals meeting the study criteria, most were women (73.7%), aged 35-54 years (48.0%), and Medicare program participants (36.8%). In total, 49.7% of inpatients with MS had 1-2 comorbid medical conditions and 23.7% had 3 or more. Having 3 or more comorbidity conditions associated with increased adjusted odds of the 30-day readmission (adjusted odds ratio [AOR] 1.92, 1.34-2.74). Anemia (AOR 1.62, 1.22-2.14), rheumatoid arthritis/collagen vascular diseases (AOR 2.20, 1.45-3.33), congestive heart failure (AOR 2.43, 1.39-4.24), chronic pulmonary disease (AOR 1.35, 1.02-1.78), diabetes with complications (AOR 2.27, 1.45-3.56), hypertension (AOR 1.25, 1.03-1.53), obesity (AOR 1.35, 1.05-1.73), and renal failure (AOR 1.68, 1.06-2.67) were associated with the 30-day readmission. Medicare insurance and nonroutine discharge were also associated with readmission, whereas patient characteristics (sex, age, and socioeconomic status) were not. The most frequent (26.7%) reason for readmission was multiple sclerosis. Ninety-day analyses produced similar findings. Comorbid diseases were associated with the readmission for persons with multiple sclerosis. Evaluations of the real-world effectiveness for DMTs in reducing hospitalizations in patients with MS may need to consider comorbid disease burden and management.
Identifiants
pubmed: 32642327
doi: 10.1212/CPJ.0000000000000838
pii: NEURCLINPRACT2018031047
pmc: PMC7292556
doi:
Types de publication
Journal Article
Langues
eng
Pagination
255-264Informations de copyright
© 2020 American Academy of Neurology.
Références
Int Psychogeriatr. 2014 Jul;26(7):1221-9
pubmed: 24735786
Neurology. 2016 Apr 5;86(14):1287-1295
pubmed: 26944268
Neurology. 2014 Sep 2;83(10):929-37
pubmed: 25085638
J Neurol. 2014 Sep;261(9):1781-8
pubmed: 24972678
Neurology. 2012 Sep 4;79(10):1049-55
pubmed: 22914826
Lancet. 2002 Apr 6;359(9313):1221-31
pubmed: 11955556
Ther Adv Neurol Disord. 2013 Jul;6(4):237-48
pubmed: 23858327
Neurology. 2015 Jul 21;85(3):240-7
pubmed: 26019190
J Gerontol A Biol Sci Med Sci. 2002 Mar;57(3):M173-7
pubmed: 11867654
Ann Fam Med. 2009 Jul-Aug;7(4):357-63
pubmed: 19597174
Mult Scler Relat Disord. 2015 Jul;4(4):296-303
pubmed: 26195046
Neurology. 2015 Jan 27;84(4):350-8
pubmed: 25540309
J Med Econ. 2016;19(5):497-505
pubmed: 26706292
Med Care. 2009 Jun;47(6):626-33
pubmed: 19433995
Neurology. 2009 Jan 13;72(2):117-24
pubmed: 18971448
Clin Orthop Relat Res. 2014 Sep;472(9):2878-86
pubmed: 24867450
Disabil Rehabil. 2018 Jul;40(15):1842-1848
pubmed: 28374631
Med Care. 2017 Jul;55(7):698-705
pubmed: 28498196